Skip to main content

Table 2 Treatment response of H101 group and control group

From: Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC)

  Overall H101(none + Anti-HBV Therapy,P = 0.162) Control P value
     0.010
CR 38(21.7 %) 25 (28.7 %)(16 + 9) 13(14.8 %) 0.017
PR 47(26.9 %) 28(32.2 %)(21 + 7) 19(21.6 %) 0.172
SD 57(32.6 %) 23(26.4 %)(14 + 9) 34(38.6 %) 0.107
PD 33(18.9 %) 11(12.6 %)(4 + 7) 22(25 %) 0.011
  1. All patients enrolled in H101 group were screened to sort out cases with anti-HBV therapy or without anti-HBV therapy.
  2. None: Patients treated by H101 without anti-HBV therapy.
  3. Anti-HBV Therapy: Patients treated by H101 with anti-HBV therapy session.